CIK 0000730272
- Large accelerated filer
REPLIGEN CORP
Sign in to watch- Ticker
- RGEN
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 042729386
- Phone
- +1 781-449-9560
- Business address
- 41 SEYON STREET, BUILDING 1, SUITE 100, WALTHAM, MA, 02453
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $5,953,260
- in 5 filings, $6.0M under 10b5-1 plans
Net −$5,953,260. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-03-18 | Pax Margaret Director | Grant or award · Stock Option (Right to Buy) | +2,236 | 2,236 | ||
| 2024-03-11 | KURIYEL RALF Senior VP, R&D | Option exercise | +1,271 | $86.10 | $109K | 27,777 |
| 2024-03-11 | KURIYEL RALF Senior VP, R&D | Sale | −3,517 | $193.73 | $681K | 24,260 |
| 2024-03-11 | KURIYEL RALF Senior VP, R&D | Option exercise · Stock Option (Right to Buy) | +1,271 | 0 | ||
| 2024-03-08 | Hunt Anthony Chief Executive Officer | Option exercise 10b5-1 | +1 | $16.55 | $17 | 201,956 |
| 2024-03-08 | Hunt Anthony Chief Executive Officer | Sale 10b5-1 | −3,377 | $195.49 | $660K | 198,579 |
| 2024-03-08 | Hunt Anthony Chief Executive Officer | Sale 10b5-1 | −6,228 | $196.32 | $1.2M | 192,351 |
| 2024-03-08 | Hunt Anthony Chief Executive Officer | Sale 10b5-1 | −1,666 | $197.39 | $329K | 190,685 |
| 2024-03-08 | Hunt Anthony Chief Executive Officer | Sale 10b5-1 | −1,347 | $198.55 | $267K | 189,338 |
| 2024-03-08 | Hunt Anthony Chief Executive Officer | Sale 10b5-1 | −1,822 | $199.53 | $364K | 187,516 |
| 2024-03-08 | Hunt Anthony Chief Executive Officer | Sale 10b5-1 | −1,305 | $200.56 | $262K | 186,211 |
| 2024-03-08 | Hunt Anthony Chief Executive Officer | Sale 10b5-1 | −806 | $201.75 | $163K | 185,405 |
| 2024-03-08 | Hunt Anthony Chief Executive Officer | Sale 10b5-1 | −156 | $202.55 | $32K | 185,249 |
| 2024-03-08 | Hunt Anthony Chief Executive Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | +1 | 0 | ||
| 2024-03-07 | Hunt Anthony Chief Executive Officer | Shares withheld for taxes | −2,867 | $195.72 | $561K | 201,955 |
| 2024-03-07 | KURIYEL RALF Senior VP, R&D | Shares withheld for taxes | −386 | $195.72 | $76K | 26,506 |
| 2024-03-07 | Bylund James Chief Operating Officer | Shares withheld for taxes | −1,206 | $195.72 | $236K | 21,035 |
| 2024-03-07 | Gebski Christine See Remarks | Shares withheld for taxes | −386 | $195.72 | $76K | 27,753 |
| 2024-03-05 | Hunt Anthony Chief Executive Officer | Shares withheld for taxes | −7,275 | $195.52 | $1.4M | 204,822 |
| 2024-03-05 | Bylund James Chief Operating Officer | Shares withheld for taxes | −22 | $195.52 | $4K | 22,241 |
Page 12 of 23 · 455 trades